Innovent Biologics

Innovent Biologics is a Chinese biopharmaceutical company that has been active in the global out-licensing market for innovative drugs. Per a 峰瑞资本 year-end review, the company reached a notable pipeline licensing deal with Takeda Pharmaceutical Company in October 2025, which helped push China's total innovative drug out-licensing value past $100 billion . elsewhere's corpus does not contain additional details on the company's founding, pipeline specifics, or broader corporate profile beyond this transaction.